16P Neutrophil-lymphocyte ratio as a prognostic marker in a resource constraint setting for metastatic malignancies treated with immune checkpoint inhibitors
ConclusionPatients with low NLR had a significantly better response rate and overall survival. In a resource and cost constraint setting, a simple inexpensive test such as NLR would not only be prognostic, but can help in choosing treatment strategies in scenarios where PDL-1 expression does not carry any implication such as in 2nd line mRCC and 2nd line mNSCLC. Also with the advent of combination regimens in 1st line setting (chemo+ ICI in mNSCLC and oral TKI+ICI in mRCC), large scale studies need to be done on whether those with low NLR can benefit with only single agent ICI which would have an impact in not only lowerin...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
143P Association of PTPRT mutation with survival of immune checkpoint inhibitor in patients with cancer
ConclusionWe demonstrated that PTPRT mutation can predict survival benefit from cancer ICI therapy. PTPRT mutation might be an important component of the immunogenetic landscape and should be integrated into predictive biomarker panels for ICI therapy and be validated in future prospective clinical trials.Legal entity responsible for the studyHerui Yao.FundingThis study was supported by grants from the National Natural Science Foundation of China (81372819, 81572596, U1601223), the Natural Science Foundation of Guangdong Province (2017A030313828), the Guangzhou Science and Technology Program (201704020131), the Sun Yat-Sen...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
85P Impact of digital patient monitoring (DPM) on quality of clinical care of cancer immunotherapy (CIT)-treated patients (pts) with advanced/metastatic non-small cell lung cancer (a/mNSCLC)
ConclusionThe DPM tool educated and empowered pts and saved time on symptom reporting. It also improved care quality, efficiency and pt –HCP communication and enabled earlier symptom management, highlighting the contributions of DPM to clinical care.Editorial acknowledgementSupport for third-party writing assistance for this abstract, furnished by Katie Wilson, PhD, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.Legal entity responsible for the studyF. Hoffmann-La Roche Ltd, Basel, Switzerland.FundingF. Hoffmann-La Roche Ltd, Basel, Switzerland.DisclosureO.O. Schmalz: Advisory / Cons...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
33P Tumour mutational burden ring trial: Evaluation of targeted next-generation sequencing platforms for implementation in clinical practice
ConclusionOur data show that assays from different providers can be used to predict TMB. However, samples with a TMB value around the cut-off of 10 mut/Mb are challenging and interpretation should occur with caution. Further studies are required before implementing these assays in routine clinical diagnosis.Legal entity responsible for the studyThe authors.FundingBristol-Myers Squibb.DisclosureS. Lambin: Research grant / Funding (institution): Bristol-Myers Squibb. All other authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
92O Nivolumab plus low-dose ipilimumab as first-line treatment of advanced NSCLC: Overall survival analysis of checkmate 817
ConclusionSelect TRAE profile of NIVO + low-dose IPI was similar between cohorts A and A1. Durable OS outcomes were observed with first-line NIVO+IPI in patients with advanced NSCLC (cohort A) and were comparable to CheckMate 227; although as expected, comorbidities and/or poor performance status impacted outcomes in cohort A1.Clinical trial identificationNCT02869789.Editorial acknowledgementWriting and editorial assistance was provided by Mhairi Laird, PhD, of Caudex and funded by Bristol-Myers Squibb.Legal entity responsible for the studyBristol-Myers Squibb.FundingBristol-Myers Squibb.DisclosureF. Barlesi: Honoraria (se...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
69P Clinical biomarkers as predictors of immunotherapy (IT) benefit in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pt)
ConclusionIn our cohort, Alb levels and BMI were strong factors predicting outcomes of IT-treated R/M HNSCC pt. These results suggest that NS should be considered when stratifying pt in ongoing trials. In addition, the lack of prognostic value of dNLR and LDH levels deserves further investigation.Legal entity responsible for the studyVall d'Hebron Institute of Oncology.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
108P Phosphatidylserine suppresses T cells through GPR174, and co-inhibition of adenosine receptors and GPR174 synergistically enhances Th1 cytokine production
ConclusionOur findings suggest that for T cells to effectively overcome cAMP-mediated immunosuppression in the tumor microenvironment, both GPR174 and the adenosine pathway must be inhibited.Legal entity responsible for the studyOmeros Corporation.FundingOmeros Corporation.DisclosureM.A. Gavin: Shareholder / Stockholder / Stock options, Full / Part-time employment: Omeros Corporation. A. Gragerov: Shareholder / Stockholder / Stock options, Full / Part-time employment: Omeros Corporation. E. Espling: Shareholder / Stockholder / Stock options, Full / Part-time employment: Omeros Corporation. A. Rohde: Shareholder / Stockhold...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
127TiP PROPEL: A phase I/II trial of bempegaldesleukin (NKTR-214) in combination with pembrolizumab (pembro) in patients (pts) with advanced solid tumours
AbstractBackgroundCheckpoint Inhibitors (CPIs), are now part of standard treatment in many advanced solid tumors, including metastatic non-small cell lung cancer (mNSCLC). However, novel, more effective CPI combinations are needed to broaden, deepen, and prolong responses, especially for pts with poor prognostic features or negative predictive clinical factors for CPI benefit, including PD-L1 negative (-) status. Bempegaldesleukin (BEMPEG; NKTR-214) is a CD122-preferential IL-2 pathway agonist designed to provide sustained signaling through the IL-2 βγ receptor. BEMPEG + CPI has demonstrated promising efficacy and can co...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
155P Interleukin 17F and vasculogenic mimicry: Potential therapeutic targets in oral tongue cancer?
ConclusionOur findings confirm the role of VM in OTSCC carcinogenesis. Here, we suggest that IL-17F counteracts the tumorigenic activity in OTSCC, in part, through the antiangiogenic effect in the tumour microenvironment, and hence further studies are warranted. Harnessing IL-17F in the current management approaches in advanced OTSCC patients may lead to promising immunotherapeutic strategies against OTSCC.Legal entity responsible for the studyUniversity of Helsinki.FundingUniversity of Helsinki, Doctoral program in clinical research (KLTO).DisclosureThe author has declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
144P Loss of BAP-1 influences the activation of p52 and RelB proteins in the Inflammatory microenvironment of uveal melanoma
ConclusionOur preliminary data reveal that in an inflammation group loss of BAP-1 showed the synergistic role with the activation of NC-NF κB proteins and are the poor prognostic indicators of overall survival.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
17P Association of lung immune prognostic index (LIPI) with survival of first line immune checkpoint inhibitors single agent or in combination with chemotherapy in untreated advanced NSCLC patients
ConclusionPretreatment LIPI correlates with ICI survival in monotherapy and in combination with chemotherapy in front-line in advanced NSCLC pts. The correlation is not statistically significant in the chemotherapy alone group. The value of LIPI for ICI upfront should be explored in prospective clinical trials.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureE. Auclin: Travel / Accommodation / Expenses: Mundipharma; Speaker Bureau / Expert testimony: Sanofi Genzyme. D. Planchard: Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (insti...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
86P A novel ImmunoScore, based on clinical and blood biomarkers, as prognostic model for immunotherapy in NSCLC
ConclusionBaseline evaluation of clinical and blood biochemical parameters can be a tool to predict outcome in patients treated with ICIs for aNSCLC. Moreover, combining them in ImmunoScore may help to identify pts candidates to second or subsequent Iines of therapy who most likely will benefit from ICIs.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
43P Enhancing the therapeutic effect of dendritic cell therapy by oncolytic adenovirus 3 encoding CD40-ligand
ConclusionTo conclude, CD40L armed oncolytic adenovirus 3 improves DC therapy by favorable alteration of tumor microenvironment. These findings support clinical trials where DC therapy is enhanced with oncolytic adenovirus.Legal entity responsible for the studyCancer Gene Therapy Group, University of Helsinki.FundingUniversity of Helsinki.DisclosureV. Cervera-Carrascon: Full / Part-time employment: TILT Biotherapeutics Ltd. J.M. Santos: Full / Part-time employment: TILT Biotherapeutics Ltd. A. Hemminki: Shareholder / Stockholder / Stock options, Full / Part-time employment, Officer / Board of Directors: TILT Biotherapeutic...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
34P Development of LAG-3 nanobodies as potent cancer imaging tracers
ConclusionNb3132 showed excellent in vivo imaging capacities to specifically identify LAG-3 expressing immune cells within the tumor site. These findings support the predictive potential of Nb3132 to noninvasively detect LAG-3 by nuclear imaging and to guide treatment decisions in future, improving the shortcomings of using full-sized antibody formats as diagnostic tracers.Legal entity responsible for the studyGeert Raes.FundingKom op tegen kanker and FWO flanders.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
93O First results of phase I/II studies evaluating viral vector-based heterologous prime/boost immunotherapy against predicted HLA class I neoantigens demonstrate CD8 T cell responses in patients with advanced cancers
ConclusionPatients treated with a heterologous viral vector-based immunotherapy produce remarkable CD8 T-cell responses specific for predicted HLA Class I neoantigens. These results demonstrate proof-of-concept for the immunogenicity of our novel prime/boost approach. Treatment was well tolerated without DLTs. Additional patients and data will be presented.Clinical trial identificationNCT03639714; NCT03953235.Legal entity responsible for the studyGritstone Oncology.FundingGritstone Oncology.DisclosureM.L. Johnson: Research grant / Funding (institution), Travel / Accommodation / Expenses: Genentech/Roche; Research grant / F...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
